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We investigated whether administration of the δ-opioid receptor (DOR) agonist
H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), which also activates nuclear factor
erythroid 2-related factor 2 (Nrf2), alleviated chronic inflammatory and/or neuropathic
pain and inhibited the depressive-like behaviors associated with persistent neuropathic
pain. The possible mechanisms implicated were also assessed. We evaluated the
following effects in male C57BL/6J mice with inflammatory pain induced by complete
Freund’s adjuvant or neuropathic pain caused by the chronic constriction of sciatic
nerve: (1) the antinociceptive effects of UFP-512; (2) the effects of UFP-512 on the
expression of Nrf2, heme oxygenase 1 (HO-1), NAD(P)H quinone oxidoreductase 1,
phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), inducible nitric oxide synthase,
DOR, and mitogen-activated protein kinases (MAPK) in the spinal cord of animals with
inflammatory or neuropathic pain; (3) the antinociceptive effects of the coadministration
of UFP-512 with the Nrf2 activator sulforaphane (SFN); and (4) the antidepressant effects
of UFP-512 in animals with depressive-like behaviors associated with neuropathic pain.
Our results demonstrated that the intraperitoneal administration of UFP-512 inhibited
chronic inflammatory and neuropathic pain and reduced the depressive-like behaviors
associated with persistent neuropathic pain. The antiallodynic effects of UFP-512 were
significantly augmented when it was coadministered with SFN in both types of chronic
pain. The administration of UFP-512 increased/reestablished the spinal cord protein
levels of Nrf2 and HO-1 in mice with inflammatory or neuropathic pain. However, while
during inflammatory pain UFP-512 inhibited spinal c-Jun N-terminal kinase (JNK) and
extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation induced by peripheral
inflammation. This DOR agonist blocked the spinal activated PI3K/Akt signaling pathway
under chronic neuropathic pain conditions, but it did not alter the enhanced protein
levels of p-JNK or p-ERK1/2 induced by sciatic nerve injury. These results revealed the
antinociceptive and antidepressant effects of UFP-512 in animals with chronic pain and
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the different mechanism of action of this DOR agonist in the presence of inflammatory or
neuropathic pain. Our data also suggest the administration of UFP-512 as an alternative
for the treatment of chronic pain and the depressive-like behaviors associated with
neuropathic pain.
Keywords: analgesia, depression, Nrf2 transcription factor, delta opioid receptors, oxidative stress, chronic
pain, UFP-512
INTRODUCTION
Chronic pain is a complex experience that is composed
of sensory and affective components. Therefore, when pain
becomes persistent or severe causes great suffering that presents
an important clinical problem with enormous economic and
social burdens (Monti and Caporali, 2015). One factor that
contributes to the intractable nature of chronic pain is the
existence of comorbidities associated such as depression, which
also negatively influence the perception of pain and create
a vicious circle that eventually leads to unwanted results
(Kawai et al., 2017).
Chronic inflammatory and neuropathic pains are difficult to
treat because actual therapies, such as NSAIDs, antidepressants,
and antiepileptics, have several side effects, and these agents do
not effectively alleviate pain and/or the associated emotional
disorders. The opioid system plays a crucial role in pain control,
and activation of µ-(MOR), δ-(DOR), and κ-opioid receptors
produces analgesia (Pol, 2007; Cahill et al., 2014; Albert-
Vartanian et al., 2016; Bodnar, 2016). However, it is curious that
while the administration of MOR agonists is highly effective for
the treatment of inflammatory pain, these agents exhibit limited
efficacy in neuropathic pain and produce several adverse side
effects, such as sedation, constipation, and respiratory depression.
In contrast, and although the administration of several DOR
agonists produce limited analgesic effects in acute pain, these
agonists reduced chronic inflammatory and neuropathic pain
with similar efficacy (Pradhan et al., 2011). Moreover, DOR
knockout (KO) mice exhibited increased inflammatory and
neuropathic pain responses when submitted to an inflammatory
or injury stimulus (Nadal et al., 2006), which supports the
hypothesis of DOR agonists as an interesting alternative
for the treatment of chronic inflammatory and neuropathic
pain. However, comparisons of the antinociceptive effects of
several DOR agonists, such as [D-Ser2, Leu5, Thr6]-enkephalin
(DSLET) and (+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-
piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC-
80), in inflammatory and neuropathic pain were only performed
in models of acute inflammatory pain (formalin test) or in
the early stages of neuropathic pain (16 days after surgery)
(Obara et al., 2009). Therefore, to the present study we
evaluated the antinociceptive effects produced by another
specific DOR agonist, H-Dmt-Tic-NH-CH(CH2-COOH)-Bid
(UFP-512), in animals with chronic inflammatory (14 days
after induction) or neuropathic (28 days after surgery) pain.
We used UFP-512 because this agonist did not produce
convulsions or alter locomotor activity, and it exhibits
anxiolytic and antidepressant properties without signs of
tolerance after chronic administration in contrast to other DOR
agonists, for example, UFP-502 (Vergura et al., 2006, 2008;
Aguila et al., 2007).
Several studies also showed the potential use of some
DOR agonists, such as [D-Pen2,D-Pen5]-enkephalin (DPDPE),
SNC-80, and UFP-512, as antidepressant drugs (Vergura et al.,
2008; Lutz and Kieffer, 2013), and these effects were also
confirmed by an increase in depressive-like behaviors in
DOR-KO mice in different depressive animal models (Filliol
et al., 2000). It is also well known that persistent neuropathic
pain is associated with several comorbidities, such as depression,
which is difficult to treat with typical antidepressants (La
Porta et al., 2016). Notably, we recently demonstrated that
treatment with the nuclear factor erythroid 2-related factor 2
(Nrf2) inducer sulforaphane (SFN) inhibited the depressive-like
behaviors linked with chronic neuropathic pain (Ferreira-
Chamorro et al., 2018). In vitro studies also revealed that UFP-512
induced activation of Nrf2 (Cao S. et al., 2015). Therefore,
we evaluated the possible antidepressant effects of UFP-512 in
animals with depressive-like behaviors associated with persistent
neuropathic pain.
The contribution of oxidative stress to central and peripheral
sensitization (Meeus et al., 2013; Riego et al., 2018) and
the protective role played by Nrf2 in reducing oxidative
stress via enhancing the expression of several antioxidant or
detoxification enzymes, including heme-oxygenase 1 (HO-1) and
NAD(P)H quinone oxidoreductase 1 (NQO1), is well recognized
(Nguyen et al., 2009). Recent works demonstrated that the
administration of Nrf2 inducers reduced inflammatory (Redondo
et al., 2017) and neuropathic pain (Negi et al., 2011; McDonnell
et al., 2017a; Wang and Wang, 2017) via activation of the
Nrf2/HO–1/NQO1 signaling pathway and/or inhibition of the
synthesis of pro-inflammatory mediators and mitogen-activated
protein kinases (MAPK) activation (Negi et al., 2011; McDonnell
et al., 2017b; Redondo et al., 2017; Wang and Wang, 2017). Based
on these findings and that UFP-512 exerts its cytoprotective
effects in cell cultures via activation of the Nrf2/HO–1/NQO1
pathway (Cao S. et al., 2015), we evaluated whether the inhibitory
effects of this DOR agonist during chronic inflammatory or
neuropathic pain were also produced via activation of this
antioxidant pathway and/or reduction of the inflammatory and
nociceptive responses implicated in the maintenance of chronic
pain. In addition and due to we previously demonstrated that
the activation of Nrf2 following SFN administration increased
the antinociceptive effects of DOR and MOR agonists during
inflammatory and neuropathic pain (McDonnell et al., 2017a;
Redondo et al., 2017; Ferreira-Chamorro et al., 2018), the
potential improvement of the antinociceptive effects of UFP-512
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by its coadministration with SFN in animals with inflammatory
or neuropathic pain was also evaluated.
We assessed the following effects in a mouse model of
inflammatory pain induced by the subplantar injection of
complete Freund’s adjuvant (CFA) and a neuropathic pain model
caused by chronic constriction of the sciatic nerve (CCI): (1) the
antiallodynic and antihyperalgesic effects of the intraperitoneal
administration of UFP-512 in chronic inflammatory and
neuropathic pain; (2) the reversal of the antinociceptive effects
of UFP-512 by the specific DOR antagonist, naltrindole, and the
unspecific opioid antagonist, naloxone; (3) the antinociceptive
effects of the coadministration of SFN with a low dose of UFP-512
in animals with chronic inflammatory and neuropathic pain;
(4) the antidepressant effects of UFP-512 on the depressive-like
behaviors linked to persistent neuropathic pain; and (5) the
effects of this DOR agonist on the expression of Nrf2, HO-1,
NQO1, inducible nitric oxide synthase (NOS2), phosphoinositide
3-kinase (PI3K)/protein kinase B (Akt), DOR, c-Jun N-terminal
kinase (JNK), and extracellular signal regulated kinase 1/2




The animals to carry out the experimental procedures were
7-week old male C57BL/6J mice, between 21 and 25 g of weight,
obtained from Envigo Laboratories (Barcelona, Spain). They were
accommodated in a room with 12 h/12 h light/dark conditions,
under controlled temperature of 22◦C and humidity of 66%. They
had free access to food and water. After a minimum of 7 days
from their arrival, animals were used for doing the experiments.
All experiments were conducted between 9:00 a.m. and 5:00 p.m.,
and executed in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Animals and
approved by the local Committee of Animal Use and Care of the
Autonomous University of Barcelona. All efforts were made to
minimize the number of animals used and their suffering.
Induction of Inflammatory Pain
Inflammatory pain was induced by the subplantar injection
of 30 µl of CFA (F5881, Sigma–Aldrich, St. Louis, MO,
United States) in the right hind paw under isoflurane anesthesia
(3% induction, 2% maintenance) according to the method used
by our group (Leánez et al., 2009). Animals were tested at
14 days after CFA injection. Contralateral hind paws were
used as controls.
Induction of Neuropathic Pain
Neuropathic pain was caused by the chronic constriction
of sciatic nerve (CCI). Nerve ligation was performed under
isoflurane anesthesia (3% induction, 2% maintenance). Blunt
dissection was made to segregate the biceps femoris from the
gluteus superficialis on the right side. The nerve was tied by
three ligatures (4/0 silk) around it, leaving 1 mm spacing and
taking care to preserve epineural circulation, in accordance to
the method used by our group (Hervera et al., 2013). Animals
were tested at 28 days after surgery. Sham-operated mice, whose
surgery was the same as described above without sciatic nerve
ligation, were used as controls.
Nociceptive Behavioral Tests
Mechanical allodynia was evaluated by measuring the hind
paw withdrawal response to the stimulation with the von Frey
filament test. Mice were placed into methacrylate cylinders
(20 cm high × 9 cm in diameter) on a lifted wire grid across
which von Frey filaments (North Coast Medical, Inc., San Jose,
CA, United States) were applied to each hind paw by using the
up/down paradigm described by Chaplan et al. (1994). After
1 h of habituation, test was started with the filament of 0.4 g
and the strength of the following filament was decreased or
increased in accordance with the response. The filament of 3.0 g
was used as a cutoff. The threshold of response was calculated
from the sequence of filament strength used during the up/down
procedure utilizing an Excel program (Microsoft Iberia SRL,
Barcelona, Spain), which includes curve fitting of the data. A clear
paw withdrawal, licking, or shaking the paw was considered to be
a nociceptive-like response.
Thermal hyperalgesia was evaluated by measuring hind paw
withdrawal latency in response to radiant heat using the plantar
test (Ugo Basile, Italy) as previously described by Hargreaves et al.
(1988). Animals were placed in methacrylate cylinders (20 cm
high × 9 cm diameter) on a glass surface and after 1 h of
habituation, the heat source was positioned under the plantar
surface of the hind paw and activated with a light beam intensity.
A cut-off or 12 s was used to avoid tissue damage. The mean paw
withdrawal latencies of each hind paw were determined by the
average of three separated trials, taken at 5 min intervals.
In CCI-injured mice, thermal allodynia to a cold stimulus was
also measured using the cold plate test (Ugo Basile, Italy) and
according to the method described by Bennett and Xie (1988).
Each animal was placed on the cold plate at 4 ± 0.5◦C and the
number of elevations of each hind paw was recorded for 5 min.
Depression-Like Behavior Test
Evaluation of depressive-like behaviors was performed using
the tail suspension test (TST), in which the total duration of
immobility of the animal was quantified according to the method
described by Steru et al. (1985), with some modifications. Briefly,
mice were suspended by the tail from a horizontal wooden bar
(35 cm above the floor) using adhesive tape (1 cm from the tip
of the tail). The immobility time in seconds was recorded over
a total period of 6 min. All the behavioral experiments were
executed by an experimenter blinded to the treatment applied.
Western Blot Analysis
Mice were euthanized by cervical dislocation at 14 days after
CFA injection (inflammatory pain) or 28 days after sciatic
nerve ligation (neuropathic pain). Tissues from the ipsilateral
side of the lumbar section of the spinal cord were extracted,
frozen in liquid nitrogen, and stored at −80◦C until use.
Samples of each tissue from three animals were pooled into
one experimental sample to obtain the necessary protein levels
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to perform western blot. The protein levels of Nrf2, HO-1,
NQO1, NOS2, PI3K, p-Akt, DOR, p-JNK, and p-ERK1/2 were
analyzed. Tissue homogenization was made in ice cold lysis
buffer (50 mM Tris Base, 150 nM NaCl, 1% NP-40, 2 mM
EDTA, 1 mM phenylmethylsulfonylfluoride, 0.5 Triton X-100,
0.1% sodium dodecyl sulfate, 1 mM Na3VO4, 25 mM NaF,
0.5% protease inhibitor cocktail, and 1% phosphatase inhibitor
cocktail). All reagents were obtained from Sigma–Aldrich,
except for NP-40, which was acquired from Calbiochem
(Darmstadt, Germany). After crude homogenate solubilization
(1 h at 4◦C), sonification (10 s), and centrifugation (15 min
at 4◦C) at 700 g, the supernatant (60 µg of total protein) was
mixed with 4× laemmli loading buffer and loaded onto 4%
stacking/10% separating sodium dodecyl sulfate polyacrylamide
gels. Afterward, the proteins were electrophoretically transferred
onto PVDF membranes (120 min). Then, they were blocked
(1 h and 15 min) with phosphate-buffered saline plus 5%
nonfat dry milk or Tris-buffered saline with Tween 20 plus
5% nonfat dry milk or 5% of bovine serum albumin. After
that, an overnight incubation at 4◦C was made with specific
rabbit primary antibody anti Nrf2 (1:160; ab62352, Abcam,
Cambridge, United Kingdom), NOS2 (1:160; ab204017,
Abcam, Cambridge, United Kingdom), HO-1 (1:150;
ab137749, Abcam, Cambridge, United Kingdom), PI3K (1:200;
ab232997, Abcam, Cambridge, United Kingdom) and DOR
(1:300; AB1560 Merck, Billerica, MA, United States), anti-NQO1
(1:250, N5288, Sigma–Aldrich, St. Louis, MO, United States),
p-Akt (1:200; 9271, Cell Signaling Technology, Danvers, MA,
United States), Akt (1:200; 9272, Cell Signaling Technology,
Danvers, MA, United States), p-JNK (1:250; 9251, Cell Signaling
Technology, Danvers, MA, United States), JNK (1:250; 9252,
Cell Signaling Technology, Danvers, MA, United States),
p-ERK1/2 (1:250; 9101, Cell Signaling Technology, Danvers,
MA, United States), and ERK1/2 (1:250; 9102, Cell Signaling
Technology, Danvers, MA, United States). Blots were
incubated for 1 h at room temperature with a horseradish
peroxidase-conjugated anti-rabbit secondary antibody (GE
Healthcare, Little Chalfont, United Kingdom) to detect proteins,
which were then visualized by chemiluminescence reagents
(ECL kit; GE Healthcare, Little Chalfont, United Kingdom)
and exposition onto hyper film (GE Healthcare, Little Chalfont,
United Kingdom). The intensity of the blot was quantified by
using densitometry. A rabbit anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) antibody (1:5000; ABS16, Merck,
Billerica, MA, United States) was used as a loading control.
Experimental Procedure
First of all, in both inflammatory and neuropathic pain models,
behavioral baseline responses were measured in the following
order: von Frey filaments, plantar test, and/or cold plate test.
At 14 days after CFA injection or at 28 days after surgery, the
antinociceptive effects produced by 1, 3, 10, 20, and 30 mg/kg of
UFP-512 were tested according to the sequence described above.
UFP-512 was injected intraperitoneally and the nociceptive
responses were tested 1 h later in accordance to our previous
pilot studies and another work (Aguila et al., 2007). In the
inflammatory pain model, the contralateral hind paw was used
as a control (n = 6 animals per dose), while in neuropathic
pain model, sham-operated animals were used as control (n = 6
animals per dose).
The reversibility of the antinociceptive effects of 30 mg/kg
UFP-512, which produces the maximal antiallodynic and
antihyperalgesic effects after peripheral inflammation and sciatic
nerve injury, with the subcutaneous administration of the
specific DOR antagonist, naltrindole (4 mg/kg) and the
unspecific opioid antagonist, naloxone (1 mg/kg) was evaluated
14 days after CFA injection or 28 days after surgery (n = 6
animals per group). The doses of all tested antagonists were
selected according to previous works (Hervera et al., 2013;
Carcolé et al., 2014).
In order to study the possible enhancement of the analgesic
effects of UFP-512 induced by SFN, in other set of experiments we
evaluated the antiallodynic and antihyperalgesic effects produced
by the intraperitoneal administration of a low dose of UFP-512
(1 mg/kg) combined with 10 mg/kg of SFN at day 14 after
CFA injection or 28 days after surgery. The dose of SFN
was selected in accordance to other studies (Redondo et al.,
2017; Ferreira-Chamorro et al., 2018) and the dose of UFP-512
was chosen from the dose–response curves performed in this
study, as the ones that produced minimal inhibitory effects
in both pain models. SFN was intraperitoneally administrated
2 h before UFP-512 injection and the nociceptive responses
were evaluated 1 h later, in accordance to our previous works
(Redondo et al., 2017; Ferreira-Chamorro et al., 2018) (n = 6
animals per group).
In animals with neuropathic pain, at day 28 after CCI, the
antidepressant effects produced by 1 mg/kg of UFP-512 in the
TST were also assessed. Sham-operated mice were used as control
(n = 8 animals per group).
Finally, the effects of UFP-512 on the expression of
Nrf2, HO-1, NQO1, NOS2, PI3K, p-Akt, DOR, p-JNK,
and p-ERK1/2 in the ipsilateral site of spinal cords of
animals with chronic peripheral inflammation or sciatic nerve
injury were evaluated by using western blot. Naive and
sham-operated mice treated with vehicle were used as controls for
CFA-injected animals and CCI-injured mice, respectively (n = 4
samples per group).
Drugs
UFP-512 was synthetized by Balboni et al. (2002), SFN
was acquired from Merck Chemicals and Life Science S.A.U
(Madrid, Spain), and naltrindole and naloxone were purchased
in Sigma–Aldrich (St. Louis, MO, United States). UFP-512
was dissolved in saline solution (0.9%) and intraperitoneally
administered at 1, 3, 10, 20, and 30 mg/kg. SFN was
dissolved in dimethylsulfoxide (1% in saline solution 0.9%)
and intraperitoneally administered at 10 mg/kg. Naltrindole
and naloxone were also diluted in saline solution (0.9%) and
subcutaneously administered at 4 and 1 mg/kg, respectively. All
drugs were prepared daily just before use and administered in
a final volume of 10 ml/kg, at 1 h (UFP-512), 3 h (SFN), and
30 min (naltrindole and naloxone) before testing in accordance
to our previous pilot studies and other works (Aguila et al., 2007;
Hervera et al., 2013; Carcolé et al., 2014; Redondo et al., 2017;
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Ferreira-Chamorro et al., 2018). For each group treated with a
drug, the respective control group received the same volume of
corresponding vehicle.
Statistical Analysis
Data are expressed as mean ± standard error of the
mean (SEM). All the statistical analysis was carried out
using the SPSS program (version 17 for windows, IBM
España, Madrid, Spain).
In both pain models and for each nociceptive behavioral test,
the comparison of the effects produced by the intraperitoneal
administration of different doses of UFP-512 or saline was
evaluated by using a one-way ANOVA, followed by the
Student–Newman–Keuls test.
In all experiments, the antiallodynic effects in the von
Frey filaments and the antihyperalgesic effects in the plantar
test were expressed as the percentage of maximal possible
effect, where the test latencies predrug (baseline) and postdrug
administration are compared and calculated according to the
following equation:
Maximal possible effect (%) = [(drug–baseline)/(cut-off–
baseline)]× 100.
In the cold plate test, the inhibitory effects were calculated
according to the following equation:
Inhibition (%) = [(paw elevations number at baseline–paw
elevations number after drug)/paw elevations number at
baseline]× 100.
For each test, the reversal of the systemic antinociceptive
effects produced by UFP-512 with naltrindole or naloxone
as well as the effects of these antagonists administered alone
were analyzed by using a one-way ANOVA, followed by the
Student–Newman–Keuls test.
In both pain models, the comparison of the antiallodynic and
antihyperalgesic effects produced by the coadministration of SFN
with UFP-512 was assessed by using a one-way ANOVA, followed
by the Student–Newman–Keuls test.
The analysis of the antidepressant actions of UFP-512 in
animals with neuropathic pain was performed by using a two-way
ANOVA, followed by the corresponding one-way ANOVA, and
the Student–Newman–Keuls test.
The effects of UFP-512 on the protein levels of Nrf2,
HO-1, NQO1, NOS2, PI3K, p-Akt, DOR, p-JNK, and
p-ERK1/2 in the spinal cord of mice with inflammatory or
neuropathic pain were analyzed by using a one-way ANOVA,
followed by Student–Newman–Keuls test. A P < 0.05 was
considered significant.
RESULTS
Effects of UFP-512 on Mechanical
Allodynia and Thermal Hyperalgesia
Induced by Inflammatory Pain
To study the antinociceptive actions of UPF-512 during
inflammatory pain, we evaluated the effects of acute
intraperitoneal administration of 1, 3, 10, 20, and 30 mg/kg
UPF-512 on CFA-induced mechanical allodynia and thermal
hyperalgesia 14 days after injection. Our results showed
that UFP-512 administration 1 h before testing inhibited
CFA-induced mechanical allodynia (Figure 1A) and thermal
FIGURE 1 | Effects of UFP-512 on the mechanical allodynia and thermal hyperalgesia induced by CFA. The effects of acute intraperitoneal administration of different
doses (logarithmic axis) of UFP-512 on the mechanical allodynia (A) and thermal hyperalgesia (B) induced by CFA in ipsilateral (continuous lines) and contralateral
hind paws (discontinuous lines) are shown. UFP-512 was administered 1 h before testing. In both panels and for each dose assessed, ∗ indicates significant
differences vs. their respective effects in the contralateral paw, + indicates significant differences vs. the effect produced by 1 mg/kg of UFP-512 in the ipsilateral paw
and # indicates significant differences vs. the effect produced by 3 mg/kg of UFP-512 in the ipsilateral paw (P < 0.05; one-way ANOVA, followed by the
Student–Newman–Keuls test). In both tests, data are expressed as mean values of maximal possible effect (%) ± SEM; n = 6 animals per dose.
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hyperalgesia (Figure 1B) in a dose-dependent manner and
reached a maximum effect at 30 mg/kg.
The mechanical antiallodynic effects produced by 10, 20,
and 30 mg/kg UFP-512 in the ipsilateral paw of CFA-injected
mice were significantly greater than the effects produced by
each respective dose in the contralateral paw (P < 0.001,
one-way ANOVA, followed by the Student–Newman–Keuls
test). Moreover, the antiallodynic effects produced by the
administration of high doses (10, 20, or 30 mg/kg) of UFP-512
were significantly higher than the effects produced by lower
doses (1 and/or 3 mg/kg) of this DOR agonist in the
ipsilateral paw (P < 0.001, one-way ANOVA, followed by the
Student–Newman–Keuls test).
The thermal antihyperalgesic effects produced by 3, 10, 20,
and 30 mg/kg UFP-512 in the ipsilateral paw of CFA-injected
mice were also greater than the effects produced by each
respective dose in the contralateral paw (P < 0.001, one-way
ANOVA, followed by the Student–Newman–Keuls test). The
antihyperalgesic actions induced by 10, 20, or 30 mg/kg UFP-512
in the ipsilateral paw were also higher than the effects produced
by 1 and 3 mg/kg of UFP-512 in the same paw.
The intraperitoneal administration of saline did not elicit any
antinociceptive effects in the contralateral or ipsilateral paw of
CFA-injected mice in either test (data not shown).
Effects of UFP-512 on the Mechanical
Allodynia, Thermal Hyperalgesia, and
Thermal Allodynia Induced by Sciatic
Nerve Injury
To study the antinociceptive actions of UPF-512 during
neuropathic pain, we evaluated the effects of the acute
intraperitoneal administration of UFP-512 at 1, 3, 10, 20, and
30 mg/kg on the mechanical allodynia, thermal hyperalgesia,
and thermal allodynia induced by sciatic nerve injury 28 days
after surgery. Our results indicated that UFP-512 administration
1 h before testing inhibited CCI-induced mechanical allodynia
(Figure 2A), thermal hyperalgesia (Figure 2B), and thermal
allodynia (Figure 2C) in a dose-dependent manner, and 30 mg/kg
produced the maximum effect.
Therefore, the mechanical antiallodynic effects produced by
10, 20, and 30 mg/kg of UFP-512 in CCI-injured mice were
greater than the effects produced by each respective dose in
sham-operated mice and the effects produced by 1 and 3 mg/kg
of this DOR agonist in CCI-injured mice (P < 0.001; one-way
ANOVA, followed by the Student–Newman–Keuls test).
The thermal antihyperalgesic effects produced by 1, 3, 10,
20, and 30 mg/kg of UFP-512 in CCI-injured animals were
higher than the effects produced by each respective dose in
sham-operated mice (P < 0.001; one-way ANOVA, followed by
the Student–Newman–Keuls test). The antihyperalgesic effects
of 10, 20, and 30 mg/kg of UFP-512 were also higher than the
effects of 1 and 3 mg/kg in CCI-injured mice (P < 0.001; one-way
ANOVA, followed by the Student–Newman–Keuls test).
Similar effects were observed for thermal allodynia. The
antiallodynic actions produced by 3, 10, 20, and 30 mg/kg of
UFP-512 in CCI-injured mice were greater than the effects
produced by these doses in sham-operated mice (P < 0.001;
one-way ANOVA, followed by the Student–Newman–Keuls test).
The antiallodynic effects produced by high doses (10, 20, and
30 mg/kg) of UFP-512 in CCI-injured mice were greater than the
effects produced by 1 mg/kg of this drug in these animals.
Treatment with UFP-512 did not affect the contralateral
paw of CCI-injured or sham-operated mice in any experiment
(data not shown). The intraperitoneal administration of saline
did not elicit any antinociceptive effect in the contralateral
or ipsilateral paw of CCI-injured or sham-operated mice
(data not shown).
FIGURE 2 | Effects of UFP-512 on the mechanical allodynia, thermal hyperalgesia, and thermal allodynia induced by CCI. The effects of the intraperitoneal acute
administration of different doses (logarithmic axis) of UFP-512 on the mechanical allodynia (A), thermal hyperalgesia (B), and thermal allodynia (C) induced by sciatic
nerve injury in the ipsilateral hind paw of CCI-injured (continuous lines) or sham-operated mice (discontinuous lines) are represented. UFP-512 was administered 1 h
before testing. For each test and dose evaluated, ∗ indicates significant differences vs. their respective effects in sham-operated mice, + indicates significant
differences vs. the effects produced by 1 mg/kg of UFP-512 in CCI-injured mice, and # indicates significant differences vs. the effects produced by 3 mg/kg of
UFP-512 in CCI-injured mice (P < 0.05; one-way ANOVA, followed by the Student–Newman–Keuls test). Data are expressed as mean values of maximal possible
effect (%) for mechanical allodynia and thermal hyperalgesia, and inhibition (%) for thermal allodynia ± SEM; n = 6 animals per dose.
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Reversal of the Antinociceptive Effects
of UFP-512 in Animals With Inflammatory
or Neuropathic Pain
To evaluate the specificity of the antinociceptive effects
produced by a high dose of UFP-512 (30 mg/kg) during
inflammatory and neuropathic pain, mice were administered
with the specific DOR antagonist, naltrindole (4 mg/kg) and
the unspecific opioid antagonist, naloxone (1 mg/kg). UPF was
intraperitoneally administered 1 h before testing, and naltrindole
and naloxone were subcutaneously administered 30 min before
testing. Our results showed that the mechanical antiallodynic
(Figure 3A) and thermal antihyperalgesic (Figure 3B) effects
produced by UFP-512 in the ipsilateral paw of CFA-injected
animals and the mechanical antiallodynic (Figure 3C), thermal
antihyperalgesic (Figure 3D), and thermal antiallodynic
(Figure 3E) effects produced by this drug in the ipsilateral paw
FIGURE 3 | Reversion of the antiallodynic and antihyperalgesic effects of UFP-512. Reversal of the effects induced by 30 mg/kg UFP-512 on the mechanical
allodynia (A) and thermal hyperalgesia (B) induced by CFA, and on the mechanical allodynia (C), thermal hyperalgesia (D), and thermal allodynia (E) caused by CCI,
in ipsilateral paws, with the administration of the specific DOR antagonist, naltrindole (4 mg/kg), and the unspecific opioid antagonist, naloxone (1 mg/kg) are shown.
The effects of vehicle, naltrindole (4 mg/kg), or naloxone (1 mg/kg) administered alone are also represented. UFP-512 was intraperitoneally injected 1 h before testing
while both naltrindole and naloxone were subcutaneously injected 30 min before testing. For each test, ∗ represents significant differences compared to the other
groups (P < 0.05; one-way ANOVA, followed by the Student–Newman–Keuls test). Data are expressed as mean values of maximal possible effect (%) for
mechanical allodynia and thermal hyperalgesia, and inhibition (%) for thermal allodynia ± SEM (six animals for each group).
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of sciatic nerve-injured mice were reversed by the subcutaneous
administration of naltrindole and naloxone (P < 0.005; one-way
ANOVA, followed by the Student–Newman–Keuls test).
The subcutaneous administration of both antagonists
administered alone in CFA-injected animals (Figures 3A,B)
and sciatic nerve-injured mice (Figures 3C–E) did not produce
any significant effect in the ipsilateral paw of these animals.
Naltrindole and naloxone administration alone also did not
produce any effect in the contralateral paw of CFA-injected
mice or sciatic nerve-injured mice or in the ipsilateral and
contralateral paw of sham-operated mice (data not shown).
Effect of UFP-512 on the Expression of
Nrf2, HO-1, NQO1, and NOS2 in the
Spinal Cords of Animals With
Inflammatory Pain
To evaluate the possible mechanisms of the antinociceptive
effects of UFP-512 during inflammatory pain, the expression
of Nrf2, HO-1, NQO1, and NOS2 in the spinal cords of
CFA-injected mice treated with 30 mg/kg UFP-512 or vehicle was
assessed 14 days after CFA injection. We used naïve mice treated
with vehicle as controls in these experiments.
Our results showed that peripheral inflammation did not
alter the spinal cord expression of Nrf2, but Nrf2 protein
levels increased significantly in CFA-injected mice treated with
UFP-512 (P < 0.022, one-way ANOVA vs. CFA-injected mice
treated with vehicle) (Figure 4A). Peripheral inflammation did
not alter the expression of HO-1 in the spinal cord compared
to naïve animals treated with vehicle, but HO-1 levels increased
significantly in CFA-injected mice treated with UFP-512
(P < 0.011, one-way ANOVA vs. naive and CFA-injected mice
treated with vehicle) (Figure 4B). No significant differences in
NQO1 (Figure 4C) or NOS2 (Figure 4D) were observed between
the three evaluated groups.
Effect of UFP-512 on the Expression of
Nrf2, HO-1, NQO1, and NOS2 in the
Spinal Cords of Animals With
Neuropathic Pain
To assess the possible mechanisms of the antinociceptive effects
of UFP-512 during neuropathic pain, the expression of Nrf2, HO-
1, NQO1, and NOS2 in the spinal cords of CCI-injured mice
treated with 30 mg/kg of this DOR agonist or vehicle was assessed
28 days after surgery.
Reduction in Nrf2 protein levels in the spinal cord
following CCI (P < 0.007, one-way ANOVA, compared to
sham-operated mice treated with vehicle) was completely
normalized with UFP-512 administration (Figure 5A). CCI
did not alter the protein levels of HO-1, but treatment
with UFP-512 significantly increased HO-1 expression in
CCI-injured mice (P < 0.008, one-way ANOVA compared
to CCI-injured and sham-operated mice treated with vehicle)
(Figure 5B). Neither CCI nor UFP-512 treatment altered NQO1
(Figure 5C) or NOS2 (Figure 5D) expression compared to
sham-operated-mice.
Effect of UFP-512 on the Expression of
PI3K, p-Akt, DOR, p-JNK, and p-ERK1/2
in the Spinal Cords of Animals With
Inflammatory Pain
To evaluate the possible effects of UFP-512 treatment on
PI3K/p-AKT, MAPK (JNK and ERK1/2), and DOR expression
during inflammatory pain, the effects of this DOR agonist on
the protein levels of PI3K (Figure 6A), p-Akt (Figure 6B), DOR
(Figure 6C), p-JNK (Figure 6E), and p-ERK1/2 (Figure 6F)
in the spinal cords of CFA-injected mice treated with UFP-512
were also assessed.
Our results did not show any significant alterations of PI3K,
p-AKT, or DOR expression following inflammation or treatment.
In contrast, the significant increase in spinal cord protein levels of
p-JNK (P < 0.027, one-way ANOVA vs. naïve mice treated with
vehicle) and p-ERK1/2 (P < 0.024, one-way ANOVA vs. naïve
mice treated with vehicle) induced by peripheral inflammation
were reversed with UFP-512 treatment.
Effect of UFP-512 on the Expression of
PI3K, p-Akt, DOR, p-JNK, and p-ERK1/2
in the Spinal Cords of Animals With
Neuropathic Pain
To assess the possible effects of UFP-512 treatment on
PI3K/p-AKT, MAPK (JNK and ERK1/2), and DOR expression
during neuropathic pain, the effects of this DOR agonist on the
protein levels of PI3K (Figure 7A), p-Akt (Figure 7B), DOR
(Figure 7C), p-JNK (Figure 7E), and p-ERK1/2 (Figure 7F) in
the spinal cords of CCI-injured mice treated with UFP-512 were
also investigated.
Our data showed that, in contrast to the effects of peripheral
inflammation, sciatic nerve injury increased the spinal protein
levels of PI3K (P < 0.027, one-way ANOVA compared to
sham-operated mice treated with vehicle), and UFP-512 inhibited
this increase. The nerve injury-induced increased expression of
p-Akt (P < 0.029, one-way ANOVA compared to sham-operated
mice treated with vehicle) was also reversed by UFP-512
administration. No changes in the protein levels of DOR were
observed in the three groups tested.
Our results also demonstrated that, similar to inflammatory
pain, sciatic nerve injury augmented the expression of p-JNK
(P < 0.007, one-way ANOVA vs. sham-operated mice treated
with vehicle) and p-ERK1/2 (P < 0.026; one-way ANOVA vs.
sham-operated mice treated with vehicle) in the spinal cord.
However, in this case, treatment with UFP-512 did not inhibit this
increased expression.
Effects of the Coadministration of SFN
on the Antinociceptive Actions of
UFP-512 in Animals With Inflammatory or
Neuropathic Pain
To study the antinociceptive actions produced by the
administration of SFN plus UFP-512 during chronic
pain, the effects of the intraperitoneal administration of
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FIGURE 4 | Effects of UFP-512 on the expression of Nrf2, HO-1, NQO1, and NOS2 in the spinal cords of animals with peripheral inflammation. Protein levels of Nrf2
(A), HO-1 (B), NQO1 (C), and NOS2 (D) in the ipsilateral site of the spinal cords of CFA-injected mice treated with UFP-512 (CFA-UFP-512) or vehicle (CFA-vehicle)
are represented. Controls corresponding to naive mice treated with vehicle (naive-vehicle) are also shown. For each protein, ∗ indicates significant differences vs.
naïve mice treated with vehicle and + indicates significant differences vs. CFA-injected mice treated with vehicle (P < 0.05, one-way ANOVA, followed by the
Student–Newman–Keuls test). Representative examples of western blots for Nrf2 (100 kDa), HO-1 (32 kDa), NQO1 (28 kDa), and NOS2 (100 kDa) proteins in which
GAPDH (37 kDa) was used as a loading control are also shown (E). Results are expressed as mean ± SEM; n = 4 samples per group.
10 mg/kg of SFN combined with a low dose (1 mg/kg)
of UFP-512 against the mechanical allodynia and thermal
hyperalgesia caused by peripheral inflammation or sciatic nerve
injury were evaluated.
For mechanical allodynia, the coadministration of SFN with
UFP-512 produced an antiallodynic effect that was significantly
higher than either UFP-512 or SFN administration alone in
animals with inflammatory (Figure 8A; P < 0.001, one-way
ANOVA, followed by the Student–Newman–Keuls test) or
neuropathic pain (Figure 8B; P < 0.001, one-way ANOVA,
followed by the Student–Newman–Keuls test).
Regarding thermal hyperalgesia, our data showed that
the administration of SFN plus UFP-512 produced an
antihyperalgesic effect in CFA-injected mice that was higher
than these drugs administered alone (P < 0.001, one-way
ANOVA, followed by the Student–Newman–Keuls test)
(Figure 8C). The combination of both drugs tended to increase
the antihyperalgesic effects produced by each drug administered
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FIGURE 5 | Effects of UFP-512 on the expression of Nrf2, HO-1, NQO1, and NOS2 in spinal cords of animals with neuropathic pain. Protein levels of Nrf2 (A), HO-1
(B), NQO1 (C), and NOS2 (D) in the ipsilateral site of spinal cords of CCI-injured mice treated with UFP-512 (CCI-UFP-512) or vehicle (CCI-vehicle) are represented.
Controls corresponding to sham-operated mice treated with vehicle (sham-vehicle) are also shown. For each protein, ∗ indicates significant differences vs.
sham-operated mice treated with vehicle, + indicates significant differences vs. CCI-injured mice treated with vehicle, and # indicates significant differences vs.
CCI-injured mice treated with UFP-512 (P < 0.05, one-way ANOVA, followed by the Student–Newman–Keuls test). Representative examples of western blots for
Nrf2 (100 kDa), HO-1 (32 kDa), NQO1 (28 kDa), and NOS2 (100 kDa) proteins in which GAPDH (37 kDa) was used as a loading control are also shown (E). Results
are expressed as mean ± SEM; n = 4 samples per group.
separately in CCI mice (Figure 8D), but the combination
effects only differed significantly when compared to the effects
produced by SFN or vehicle administered alone (P < 0.001,
one-way ANOVA, followed by the Student–Newman–Keuls test).
The Effects of UFP-512 on the
Depressive-Like Behaviors Associated
With Neuropathic Pain
To assess the possible antidepressant effects of UFP-512 in
animals with depressive-like behaviors associated with persistent
neuropathic pain, the effects of the intraperitoneal administration
of 1 mg/kg UFP-512 in CCI-injured mice were evaluated 28 days
after surgery using the TST 1 h after injection.
Two-way ANOVA revealed a significant effect of the surgery
(P < 0.049) and treatment (P < 0.001). The increased
immobility time in CCI-injured animals (Figure 9; P < 0.001,
one-way ANOVA vs. sham-operated mice treated with saline)
was significantly reduced with UFP-512 administration. This
treatment also reduced the immobility time in sham-operated
mice (P < 0.001, one-way ANOVA vs. sham-operated mice
treated with saline). Therefore, our results confirmed the
Frontiers in Pharmacology | www.frontiersin.org 10 March 2019 | Volume 10 | Article 283
fphar-10-00283 March 22, 2019 Time: 17:58 # 11
Polo et al. UFP-512 Inhibits Inflammatory and Neuropathic Pain
FIGURE 6 | Effects of UFP-512 on the expression of PI3K, p-Akt, DOR, p-JNK, and p-ERK 1/2 in the spinal cords of animals with peripheral inflammation. Protein
levels of PI3K (A), p-Akt (B), DOR (C), p-JNK (E), and p-ERK 1/2 (F) in the ipsilateral site of spinal cords of CFA-injected mice treated with UFP-512 (CFA-UFP-512)
or vehicle (CFA-vehicle) are represented. Controls corresponding to naive mice treated with vehicle (naive-vehicle) are also shown. For each protein, ∗ indicates
significant differences vs. naive-vehicle treated mice and # indicates significant differences vs. CFA-injected mice treated with UFP-512 (P < 0.05, one-way ANOVA,
followed by the Student–Newman–Keuls test). Representative examples of western blots for PI3K (130 kDa), p-Akt (60 kDa), Akt (60 kDa), DOR (36 kDa), and
GAPDH (37 kDa) are shown in (D) and for p-JNK/total JNK protein (46–54 kDa) and p-ERK 1/2/total ERK 1/2 (42–44 kDa) in (G). Phosphorylated proteins are
expressed relative to their corresponding total proteins while the rest are relative to GAPDH. Results are expressed as mean ± SEM; n = 4 samples per group.
antidepressant effects of this DOR agonist in animals without
pain and further demonstrated its antidepressant activity in
mice with depressive-like behavior associated with persistent
neuropathic pain.
DISCUSSION
The present study revealed that the administration of UFP-512
diminished the allodynia and hyperalgesia caused by chronic
peripheral inflammation and increased Nrf2-HO-1 protein
levels in the spinal cords of these animals. This DOR agonist
also inhibited the mechanical and thermal allodynia and
thermal hyperalgesia induced by sciatic nerve ligation and
normalized and/or increased the spinal cord expression of
Nrf2 and HO-1. The antinociceptive effects of UFP-512 were
reversed by the administration of the specific DOR antagonist,
naltrindole, and the unspecific opioid antagonist, naloxone.
UFP-512 blocked the phosphorylation of JNK and ERK1/2
induced by peripheral inflammation in CFA-injected mice, and
this drug inhibited activation of PI3K/Akt in CCI animals, but
it did not alter CCI-induced JNK and ERK1/2 phosphorylation.
UFP-512 inhibited the depressive-like behavior associated with
persistent neuropathic pain, and its coadministration with SFN
improved its antiallodynic effects in animals with inflammatory
or neuropathic pain.
Our results revealed, for the first time, that treatment
with UFP-512 inhibited the allodynia and hyperalgesia caused
by peripheral inflammation or sciatic nerve injury in a
dose-dependent manner. These results are consistent with
the analgesic effects of other DOR agonists, such as DPDPE
or SNC-80, during inflammatory (Carcolé et al., 2014) or
neuropathic pain caused by nerve injury (Hervera et al., 2010)
or diabetes (Castany et al., 2016; McDonnell et al., 2017a).
Our data also revealed that analogous doses of UFP-512
produced comparable antiallodynic and antihyperalgesic effects
in animals with inflammatory or neuropathic pain. A dose
of 30 mg/kg of UFP-512, for example, similarly inhibited the
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FIGURE 7 | Effects of UFP-512 on the expression of PI3K, p-Akt, DOR, p-JNK, and p-ERK 1/2 in the spinal cords of animals with neuropathic pain. Protein levels of
PI3K (A), p-Akt (B), DOR (C), p-JNK (E), and p-ERK 1/2 (F) in the ipsilateral site of the spinal cord from CCI-injured mice treated with UFP-512 (CCI-UFP-512) or
vehicle (CCI-vehicle) are represented. Controls corresponding to sham-operated mice treated with vehicle (sham-vehicle) are also shown. For each protein,
∗ indicates significant differences vs. sham-operated mice treated with vehicle and # indicates significant differences vs. CCI-injured mice treated with UFP-512
(P < 0.05, one-way ANOVA, followed by the Student–Newman–Keuls test). Representative examples of western blots for PI3K (130 kDa), p-Akt (60 kDa), Akt
(60 kDa), DOR (36 kDa), and GAPDH (37 kDa) are shown in (D) and for p-JNK/total JNK protein (46–54 kDa) and p-ERK 1/2/total ERK 1/2 (42–44 kDa) in (G).
Phosphorylated proteins are expressed relative to their corresponding total proteins while the rest are relative to GAPDH. Results are expressed as mean ± SEM;
n = 4 samples per group.
mechanical allodynia (65%) and thermal hyperalgesia (60%) in
both pain models. These results are consistent with the similar
effectivity showed by other DOR agonists in the inhibition
of acute inflammatory (3 h) and neuropathic pain (16 days
after surgery) (Obara et al., 2009) and further demonstrated
that this analogous efficacy was also observed during chronic
inflammatory (14 days after CFA injection) and neuropathic
pain (28 days after CCI). Therefore, and considering the
few side effects of this DOR agonist compared to MOR
agonists (Aguila et al., 2007; Fernández-Dueñas et al., 2007;
Hervera et al., 2012; Bodnar, 2016), the present results support
the use of UFP-512 as an interesting treatment for chronic
pain management.
The present study only evaluated the antinociceptive effects
of systemic UFP-512 in male mice. However, the peripheral
administration of other DOR agonists, such as DPDPE, also
inhibits inflammatory and neuropathic pain (Hervera et al., 2010,
2013; Carcolé et al., 2014) and 10-fold higher dose of DPDPE is
required in female rats to produce analogous anti-hyperalgesic
responses that achieved in male rats, revealing sex differences
in the peripheral effects of this DOR agonist (Saloman et al.,
2011). Therefore, the potential peripheral antinociceptive effects
of UFP-512 in male and female rodents need to be investigated.
The reversion of the antiallodynic and antihyperalgesic
effects of UFP-512 during inflammatory or neuropathic pain
was evaluated by measuring its effects in the presence of
the specific DOR antagonist, naltrindole, and the unspecific
opioid antagonist, naloxone. Both antagonists reversed the
antinociceptive effects of UFP-512, which suggests that these
effects are mediated via DOR, although we cannot exclude a
contribution of MOR to the antinociceptive effects of UFP-512
in these experimental conditions. In accordance to our results,
previous studies of Balboni et al. (2002, 2008) also reported
that the antinociceptive effects of centrally administered UFP-512
were DOR-mediated based on the reversal by the specific DOR
antagonist, naltrindole.
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FIGURE 8 | Effects of the coadministration of UFP-512 with SFN on the mechanical allodynia and thermal hyperalgesia induced by peripheral inflammation or sciatic
nerve injury. Mechanical antiallodynic and thermal antihyperalgesic effects produced by 10 mg/kg SFN and 1 mg/kg UFP-512 intraperitoneally administered alone or
combined in animals with inflammatory (A, C) or neuropathic pain (B, D) are shown. SFN and UFP-512 were administered at 3 and 1 h before testing, respectively.
For each test, ∗ indicates significant differences vs. its respective animals treated with vehicle plus saline, + indicates significant differences vs. its respective animals
treated with vehicle plus UFP-512, and # indicates significant differences vs. its respective animals treated with SFN plus saline (P < 0.05, one-way ANOVA, followed
by the Student–Newman–Keuls test). Data are expressed as mean values of maximal possible effect (%) for mechanical allodynia and thermal hyperalgesia ± SEM;
n = 6 animals per group.
Notably, previous studies in cell cultures showed that UFP-512
stimulated the Nrf2 transcription factor (Cao S. et al., 2015),
which is a key mechanism of defense against oxidative stress
and inflammatory processes. Our results further demonstrated
that UFP-512 also enhanced the expression of Nrf2 and HO-
1 in the spinal cords of mice with peripheral inflammation
and normalized the decreased expression of Nrf2 induced by
nerve injury or enhanced the protein levels of HO-1 in the
spinal cord of sciatic nerve-injured mice. These latter results
confirmed the long-lasting state of oxidative stress that is
induced by sciatic nerve ligation in the spinal cord (Riego
et al., 2018) and revealed, for the first time, the ability of UFP-
512 to normalize this effect in vivo. Moreover and tacking
account that several Nrf2 inducers produce antinociceptive
effects during chronic pain (Negi et al., 2011; McDonnell et al.,
2017a; Redondo et al., 2017), the augment or normalization
of Nrf2 expression in the spinal cord following systemic UFP-
512 administration supports the hypothesis that Nrf2 might
be involved in the antinociceptive effects of UFP-512 in the
presence of chronic inflammatory or neuropathic pain. The
substantial improvement in the antiallodynic actions of UFP-512
induced by SFN in animals with inflammatory or neuropathic
pain suggests that the coadministration of Nrf2 activators with
UFP-512 is another interesting approach for the treatment
of chronic pain because the maximal antinociceptive effect
(approx. 60%) was induced using a small dose of UFP-512,
minimizing side effects. In accordance to our findings, other
studies also demonstrated that SFN potentiated the analgesic
effects of specific DOR agonists, such as DPDPE and SNC-80, in
animals with diabetic neuropathy (McDonnell et al., 2017a) and
improved the local antiallodynic and/or antihyperalgesic effects
of MOR agonists, for example morphine, under inflammatory
and neuropathic pain conditions (Redondo et al., 2017;
Ferreira-Chamorro et al., 2018).
The expression of HO-1, which is a relevant antioxidant
enzyme, was also increased by UFP-512 in the spinal cord of
mice with inflammatory or neuropathic pain. This result suggests
that this isoenzyme plays a role in the antinociceptive effects
produced by this DOR agonist. Others studies also demonstrated
that the administration of HO-1 inducer compounds, such
as cobalt protoporphyrin IX, improved the antinociceptive
activity of other DOR agonists during inflammatory pain
(Carcolé et al., 2014) or diabetic neuropathy (Castany et al.,
2016). In summary, these findings suggest that the Nrf2/HO-1
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FIGURE 9 | Effects of UFP-512 on the depressive-like behaviors associated
with neuropathic pain. Immobility time in seconds (s) for CCI-injured and
sham-operated mice treated with 1 mg/kg of UFP-512 or saline evaluated at
28 days after surgery in TST are represented. UFP-512 was administered 1 h
before testing. In all groups, ∗ indicates significant differences vs.
sham-operated mice treated with saline and + indicates significant differences
vs. CCI-injured mice treated with saline (P < 0.05, one-way ANOVA, followed
by the Student–Newman–Keuls test). Results are expressed as mean ± SEM;
n = 8 animals for each experimental group.
pathway is involved in the analgesic actions of UFP-512
during chronic pain.
Curiously, and in contrast to the in vitro effects (Cao S. et al.,
2015), UFP-512 treatment did not alter the unchanged expression
of another important detoxifying enzyme, NQO1, in the spinal
cords of animals with inflammatory or neuropathic pain. These
results suggest that NQO1 does not play a relevant role in the
mechanism of action of UFP-512 under chronic pain conditions.
The important role of the PI3K/Akt signaling pathway in the
development of chronic pain is well accepted. Recent studies
demonstrated the different participation of diverse PI3K isoforms
in inflammatory and neuropathic pain (Pritchard et al., 2016;
Liu et al., 2018). PI3K-β is involved in the nerve injury-induced
sensitization of the spinal cord and contributes to neuropathic
pain (Liu et al., 2018), but this β isoform does not participate in
the development of inflammatory pain (Pritchard et al., 2016).
In accordance, our findings demonstrated that sciatic nerve
ligation activated the PI3Kβ/p-Akt signaling in spinal cords, but
peripheral inflammation did not alter its expression. Notably,
UFP-512 inhibited the sciatic nerve injury-induced upregulation
of PI3K-β/p-Akt. The administration of specific inhibitors of
PI3K-β isoform also reduces neuropathic pain (Liu et al.,
2018). Therefore, the normalization of this pathway induced
by UFP-512 suggests that the antiallodynic and antihyperalgesic
effects of this DOR agonist during neuropathic pain partially
occur via the inhibition of this nociceptive pathway.
The present study also evaluated the effect of UFP-512 on the
expression of NOS2 during inflammatory and neuropathic pain.
Peripheral inflammation or sciatic nerve injury did not modify
the spinal cord protein levels of NOS2 at 14 or 28 days after
CFA-injection or CCI-induction, respectively, which is consistent
with a previous study (Redondo et al., 2017). The administration
of UFP-512 did not alter NOS2 expression in animals with
inflammatory or neuropathic pain, which indicates that this
isoenzyme is not crucial for the effects of UFP-512.
The participation of MAPKs in the development and
maintenance of chronic pain and the differential activation of
MAPK pathways in neurons and glia (microglia and astrocytes)
during inflammatory and neuropathic pain (Ji et al., 2009;
Edelmayer et al., 2014) are well documented. Thus, under
neuropathic pain conditions the expression of p-P38 is increased
in microglia, and JNK is activated in astrocytes (Cao J.
et al., 2015). Our findings support the role of MAPK in the
maintenance of chronic pain because increased expression of
p-JNK and p-ERK1/2 was observed in the spinal cords of
animals with inflammatory or neuropathic pain. But curiously,
while UFP-512 blocked the activation of these proteins in
CFA-injected mice, this DOR agonist did not alter the elevated
expression of p-JNK or p-ERK1/2 in the spinal cords of
sciatic nerve-injured animals. Perhaps, repeated administration
of this compound may be necessary to counteract the spinal
activation of JNK and ERK1/2 induced by sciatic nerve injury.
In summary, our results indicated that the alleviation of
chronic inflammatory pain of UFP-512 was mainly produced
via inhibition of JNK and ERK1/2 activation, and other
mechanisms, such as the inhibition of PI3K/p-Akt, might be
implicated in their antinociceptive effects under neuropathic
pain conditions.
In addition, no changes in the expression of DOR were
observed in the spinal cords of animals with inflammatory or
neuropathic pain, which is consistent with a previous report
(Obara et al., 2009). UFP-512 did not alter DOR expression
during inflammatory or neuropathic pain.
The antidepressant-like activity of DOR agonists is well
acknowledged. Indeed, DOR KO mice exhibit increased
depressive-like behavior (Filliol et al., 2000), and several
works demonstrated antidepressant-like effects produced by
different DOR agonists in various behavioral paradigms (Lutz
and Kieffer, 2013). In this lane, the antidepressant properties
of UFP-512 in naïve animals were previously established in
the forced swimming test (Aguila et al., 2007; Vergura et al.,
2008). However and given that persistent neuropathic pain
is generally associated with depressive-like behavior (Kawai
et al., 2017), we evaluated the possible antidepressant activity
of UFP-512 in animals with neuropathic pain. Our results
confirmed the antidepressant-like effects of this drug after
intraperitoneal administration in naïve animals (Aguila et al.,
2007) and further demonstrated that UFP-512 inhibited the
depressive-like behavior associated with persistent neuropathic
pain (28 days after surgery). These data reveal that UFP-512
alleviates neuropathic pain and inhibits the depressive-like
behavior associated with chronic pain.
CONCLUSION
In conclusion, our study revealed the antinociceptive properties
of UFP-512 in chronic inflammatory and neuropathic pain.
Activation of the Nrf2-HO-1 pathway and the inhibition of
p-JNK and p-ERK1/2 in the spinal cord may explain these effects
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in animals with inflammatory paint. Induction of the Nrf2-HO-1
pathway and blockade of PI3K/p-Akt signaling caused by nerve
injury may be the principal reason for the antinociceptive
effects of UFP-512 during neuropathic pain. Moreover,
UFP-512 exhibited antidepressant properties in animals with
depressive-like behavior associated with neuropathic pain, and
its coadministration with SFN improved the antiallodynic effects
of this DOR agonist in chronic pain. Consequently, this study
suggests the administration of UFP-512 as a new alternative for
the treatment of chronic inflammatory and neuropathic pain and
the depressive-like behavior associated with neuropathic pain.
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